



Atty. Dkt. No. 093397-0501

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: William R. Wilson et al.

Title: Anti-Cancer Combinations

Appl. No.: 10/790,943

International 9/3/2002

Filing Date:


371(c) Date:

Examiner: James D. Anderson

Art Unit: 1614

Confirmation 2176

Number:

<b>CERTIFICATE OF EXPRESS MAILING</b>	
I hereby certify that this correspondence is being deposited with the United States Postal Service's "Express Mail Post Office To Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
EM 200 053 865 US	August 20, 2008
(Express Mail Label Number)	(Date of Deposit)
Tom O'Brien	
(Printed Name)	
	
(Signature)	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to

08/25/2008 WABDELRI 00000009 10790943

02 FC:1806

180.00 OP

SVCA\_207004.1

antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

### **TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

### **RELEVANCE OF EACH DOCUMENT**

Applicant herein cite on Form PTO/SB/08, the co-pending U.S. Applications which are assigned at least in part to Cancer Research Technology (P10-P18) and at least in part to Antisoma, Inc. (U1 and U2). The Examiner is invited to review all the references cited in the co-pending U.S. applications, as well as the Office Actions issued therein. To the best of Applicants' knowledge, these documents are available to the Examiner on the U.S. Patent Office PAIR system.

Several of the documents listed on the attached PTO/SB/08 Form were cited in the International Search Reports (ISR) of the corresponding PCT applications of the co-pending U.S. Applications.

Copies of the International Search Reports for WO 03/080044 A1, WO 2004/039363 A1, WO 2005/027974 A1, WO 2007/023302 A1 and W 2007/023307 A1 are attached. These are submitted to set forth the portion of previously submitted references considered relevant by the International Searching Authority.

All of the documents are in the English-language, except F1 and F2. An English-language translation of the foreign-language document F14 has been provided. The absence of a translation or an English-language counterpart document does not relieve the PTO from its duty to consider the submitted foreign language document (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

**FEE**

A credit card payment form in the amount of \$180.00 is enclosed in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this submission under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

Aug. 20, 2008

By

Antoinette F. Konski

FOLEY & LARDNER LLP  
Customer Number: 38706  
Telephone: (650) 251-1129  
Facsimile: (650) 856-3710

Antoinette F. Konski  
Attorney for Applicant  
Registration No. 34,202